NATCO Pharma Limited has announced the launch of Everolimus Tablets 1mg, a generic version of Zortress® by Novartis, under the therapeutic class of immunosuppressants. The launch marks another milestone in NATCO’s ongoing efforts to strengthen its global presence in niche pharmaceutical segments.
The product will be marketed in the U.S. by Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International, which plans to roll out the Everolimus 1mg tablets immediately. Everolimus acts as an mTOR inhibitor immunosuppressant, primarily used for the prophylaxis of organ rejection in adult kidney and liver transplant patients.
Breckenridge had earlier launched Everolimus tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blister packs introduced in July 2021 and bottle formulations made available in June 2023. The addition of the 1mg variant now completes the product range, enhancing treatment flexibility for physicians and patients.
About NATCO Pharma Limited
Headquartered in Hyderabad, NATCO Pharma Limited is a research-driven pharmaceutical company known for developing, manufacturing, and marketing both generic and specialty pharmaceuticals, active pharmaceutical ingredients (APIs), and crop protection products. The company is a major player in oncology and targeted therapies in India and focuses on limited-competition molecules in the U.S. market.
NATCO operates nine manufacturing sites and two R&D facilities across India, all of which meet international regulatory standards. Its facilities are approved by top global health authorities, including the U.S. FDA, Brazil ANVISA, Health Canada, and WHO, enabling the company to cater to over 50 global markets.
The launch of Everolimus Tablets 1mg further reinforces NATCO’s commitment to delivering affordable and high-quality healthcare solutions worldwide while expanding its footprint in the U.S. generic drug market.
